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that continues as the receptor is internalised into endosomes. The signal
is terminated by the acidic endosomal environment, which causes li-
gand dissociation, and by subsequent receptor recycling or degradation
mediated by the multi-protein complex termed retromer (Feinstein et
al., 2011).
Retromer has two known intracellular protein-transport functions.Osteoblast
Osteoclast
Parathyroid hormone
RetromerThe recombinant parathyroid hormone (PTH) Teriparatide is the
only therapy for postmenopausal osteoporosis that increases bone
mass (i.e., is anabolic). Its therapeutic action depends on a short
“burst” of PTH in the circulation followed by a rapid return to normal
levels; if PTH levels remain high, bone loss occurs (i.e., the effect is cat-
abolic) (Frolik et al., 2003). This occurs because PTH not only stimulates
the bone forming activity of osteoblasts, but also stimulates their ability
to support osteoclast formation by producing RANKL. If PTH-induced
RANKL production persists for longer than usual, anabolic intermittent
PTH treatment can be switched to a catabolic effect (Walker et al.,
2012). This may explain why PTH therapy is not effective in all patients,
andwhy PTH anabolic effect is not sustainedwith long-term treatment.
Identifying mechanisms that control how PTH signalling is terminated
within the cell may provide new ways to design PTH-based therapies
to overcome this problem. Three recent papers including work in
EBiomedicine by Xiong et al. (Xiong et al., 2016; Chan et al., 2016;
McGarvey et al., 2016) indicate that PTH receptor signalling duration
is controlled by VPS35 and SNX27, two components of the retromer
complex.
PTH signals through PTH receptor (PTH1R). This G protein-coupled
receptor is shared with PTHrP (PTH-related protein), a paracrine factor
produced by osteoblasts essential for normal physiological boneom.2016.05.028.
edical Research, 9 Princes St.,
. This is an open access article underformation (Martin and Sims, 2013). PTH or PTHrP binding to PTH1R ini-
tiates intracellular cyclic adenosine monophosphate (cAMP) signalling
It carries protein cargo within endosomes, including internalised trans-
membrane receptors such as PTH1R, to the trans-Golgi network
(Feinstein et al., 2011); once the cargo reaches that destination it is
recycled into components used by the cell tomanufacture newproteins.
The second function is to shuttle proteinswithin endosomes back to the
plasma membrane, thereby restoring the transmembrane receptor
availability. Retromer contains a heterotrimer of vacuolar protein
sorting-associated proteins VPS26, VPS29 and VPS35, and a dimer of
membrane-associated sorting nexin (SNX) family members. These
SNX family members sort proteins to the appropriate intracellular
actin-mediated transport pathway. For instance, SNX27 directs trafﬁc
to the plasma membrane. SNX27 binds to the PTH1R through the
SNX27 PDZ domain and tethers PTH1R to the VPS35-containing
retromer complex (Chan et al., 2016; McGarvey et al., 2016). PTH and
PTHrP signalling could be modiﬁed by both functions of retromer.
VPS35 knockdown in kidney cells (Feinstein et al., 2011) and osteo-
blasts (Xiong et al., 2016) resulted in only a very slight elevation in the
cAMP response to PTH. What is more convincing is an extended cAMP
response duration reported in both studies, with cAMP levels remaining
high until at least 40min after initial exposure to PTH. VPS35 deﬁciency
might limit retrograde PTH1R transport, or impair trafﬁcking to the
plasma membrane: which of these is required to limit the cAMP re-
sponse? VPS35 overexpression increased, and depletion reduced,
PTH1R trafﬁcking to the Golgi (Xiong et al., 2016; Feinstein et al.,
2011). In addition, VPS35 or SNX27 depletion decreased PTH1R
recycling rate at the plasma membrane following PTH treatment
(Chan et al., 2016; McGarvey et al., 2016). Both VPS35 and SNX27
knockdown increased cAMP accumulation (Chan et al., 2016). Slower
PTH1R recycling may therefore sustain cAMP accumulation without
VPS35.
VPS35 and SNX27 transportmany intracellular receptors with broad
functions. Those identiﬁed to date that regulate bone metabolism in-
clude the β1 and β2 adrenergic receptors, GPR177 — a receptor thatthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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radative RANKL transport in osteoclasts (Xia et al., 2013). There are like-
ly to be additional cargoes. Unsurprisingly, global VPS35 knockouts are
early embryonic lethal, and global SNX27 knockouts exhibit a severe
skeletal phenotype (Chan et al., 2016). Speciﬁc VPS35 knockdown in
the osteoblast lineage, using osteocalcin-targeted-Cre, resulted in mild-
ly lowered bonemass in the primary spongiosa, assessed at a single time
point (Xiong et al., 2016). The cellularmechanism responsible is unclear
– serum biochemistry showed elevated markers of bone formation and
elevated serum calcium, suggesting that both bone formation and re-
sorption are high with an imbalance in favour of resorption; no
histomorphometry is reported. Further work is needed to determine
the basal effect of VPS35 deletion in osteoblasts.
Due to retromer's multiple functions, the key question from a thera-
peutic perspective is how PTH anabolic action is modiﬁed in mice with
speciﬁc VPS35 or SNX27 deletion in osteoblasts; thismust be performed
in vivo because it is not possible to model PTH anabolic action in vitro.
Mice with VPS35 deletion targeted to osteoblasts showed a greater in-
crease in bone mass in the primary spongiosa in response to PTH com-
pared to controls (Xiong et al., 2016). It must be noted that the primary
spongiosa is the regionwhere new trabeculae are formed frommineral-
ized cartilage at the growth plate, and bone mass in this region is con-
trolled by many biological processes in addition to bone formation
and resorption, such as chondrocyte differentiation and angiogenesis
(Poulton et al., 2012). Increased bonemass in this region does not relate
directly to bone remodelling inmature bone. For this reason it is not yet
clear whether VPS35 depletion in osteoblasts shifts the balance of PTH
treatment to favour an anabolic effect by reducing its pro-osteoclastic
action. Although an impaired osteoclastic response to PTH treatment
was observedwhen osteoclast precursors were co-cultured with osteo-
blasts deﬁcient in VPS35 and analysis at a single time point showed low
RANKL mRNA levels (Xiong et al., 2016), this is suggestive only. It re-
mains to be clariﬁed whether this reﬂects reduced RANKL production
in response to PTH, or a shorter duration of RANKL response, or if the ef-
fect in vivo is osteoclast-mediated at all.We can conclude that VPS35, at least through SNX27-mediated
PTH1R recycling, controls the duration of cAMP response to PTH1R in
both osteoblasts and kidney cells. How this pathway can be exploited
to improve PTH anabolic action remains to be determined.
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